Brief: AUM Biosciences Doses First Patient In Phase 2 Clinical Trial Of Aum001 In Metastatic Colorectal Cancer
30/05/2023 13:08
May 30 (Reuters) - Mountain Crest Acquisition Corp V
MCAGU.O :
* AUM BIOSCIENCES DOSES FIRST PATIENT IN PHASE 2 CLINICAL
TRIAL OF
AUM001 IN METASTATIC COLORECTAL CANCER
Source text for Eikon: ID:nGNX8TSSDR
Further company coverage: MCAGU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mountain Crest Acquisition V
See all newsBrief: Mountain Crest Acquisition Corp. V Receives Notification Of Deficiency From Nasdaq Related To Delayed Filing Of Quarterly Reports
Brief: SPAC Mountain Crest Acquisition Corp V Receives Deficiency Notification From Nasdaq On Delayed Filing Of Annual Report, Quarterly Report
Brief: Cubebio Enter Terms Of Potential Business Combination With Mountain Crest Acquisition Corp
Brief: Mountain Crest Acquisition Corp V Got Letter From Nasdaq
Brief: Mountain Crest Acquisition Corp V Says On June 27, Co Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq